葵花药业
(002737)
| 流通市值：66.05亿 | | | 总市值：66.05亿 |
| 流通股本：5.84亿 | | | 总股本：5.84亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,497,956,476.4 | 843,918,908.69 | 2,317,958,832.5 | 1,683,984,047.39 |
| 营业总成本 | 1,378,650,468.38 | 690,471,907.04 | 2,580,394,835.96 | 1,747,427,250.48 |
| 其他经营收益 | | | | |
| 营业利润 | 100,870,603.79 | 140,184,499.13 | -251,188,532.46 | 2,349,230.29 |
| 利润总额 | 99,847,076.15 | 141,487,238.05 | -271,154,705.67 | -6,234,762.74 |
| 净利润 | 85,479,307.67 | 115,792,064.38 | -297,073,301.51 | -45,914,346.86 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | 41,865.61 | -26,732.16 |
| 综合收益总额 | 85,479,307.67 | 115,792,064.38 | -297,031,435.9 | -45,941,079.02 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 3,547,216,575.99 | 3,561,876,642.52 | 3,501,812,094.42 | 3,261,322,981.89 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,757,115,505.62 | 1,793,754,607.17 | 1,826,504,962.99 | 1,862,130,393.85 |
| 资产总计 | 5,304,332,081.61 | 5,355,631,249.69 | 5,328,317,057.41 | 5,123,453,375.74 |
| 流动负债: | | | | |
| 流动负债合计 | 1,021,725,551.02 | 1,068,429,532 | 1,151,509,587.65 | 720,514,381.01 |
| 非流动负债: | | | | |
| 非流动负债合计 | 206,771,704.52 | 180,732,114.78 | 186,137,655.77 | 171,039,709.45 |
| 负债合计 | 1,228,497,255.54 | 1,249,161,646.78 | 1,337,647,243.42 | 891,554,090.46 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,917,475,557.36 | 3,948,602,437.58 | 3,838,301,016.39 | 4,052,632,698.81 |
| 股东权益合计 | 4,075,834,826.07 | 4,106,469,602.91 | 3,990,669,813.99 | 4,231,899,285.28 |
| 负债和股东权益合计 | 5,304,332,081.61 | 5,355,631,249.69 | 5,328,317,057.41 | 5,123,453,375.74 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,636,639,193.8 | 859,594,057.33 | 3,247,299,761.68 | 1,686,942,207.77 |
| 经营活动现金流出小计 | 1,611,091,223.49 | 781,487,217.43 | 2,672,334,151.33 | 1,466,618,215.57 |
| 经营活动产生的现金流量净额 | 25,547,970.31 | 78,106,839.9 | 574,965,610.35 | 220,323,992.2 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 4,777,077,668.32 | 2,369,923,403.61 | 9,353,549,311.76 | 8,150,506,423.35 |
| 投资活动现金流出小计 | 4,331,349,478.23 | 1,827,209,732.23 | 9,906,167,526.1 | 8,427,421,423.1 |
| 投资活动产生的现金流量净额 | 445,728,190.09 | 542,713,671.38 | -552,618,214.34 | -276,914,999.75 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 75,000,000 | - | 118,000,000 | 18,000,000 |
| 筹资活动现金流出小计 | 2,203,522.78 | 2,387,306.12 | 328,194,658.78 | 314,007,935.81 |
| 筹资活动产生的现金流量净额 | 72,796,477.22 | -2,387,306.12 | -210,194,658.78 | -296,007,935.81 |
| 汇率变动对现金及现金等价物的影响 | -327,085.64 | -175,358.63 | -193,176.66 | 65,213.33 |
| 现金及现金等价物净增加额 | 543,745,551.98 | 618,257,846.53 | -188,040,439.43 | -352,533,730.03 |
| 期末现金及现金等价物余额 | 1,393,665,811.06 | 1,468,178,105.61 | 849,920,259.08 | 685,426,968.48 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 543,745,551.98 | - | -188,040,439.43 | - |